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Abstract
Glutathione peroxidase 3 (GPX3) is one of the key enzymes in the cellular defense against oxidative stress and the
hepatocyte growth factor receptor, (MET) has been suggested to be influenced by the GPX3 gene expression. In a
previous microarray study performed by our group, Gpx3 was identified as a potential biomarker for rat endome-
trial adenocarcinoma (EAC), since the expression was highly downregulated in rat EAC tumors. Herein, we have
investigated the mRNA expression and Gpx3 and Met in rat EAC by real time quantitative PCR (qPCR), and the
methylation status of Gpx3. In addition we have examined the expression of GPX3 and MET in 30 human EACs of
different FIGO grades and 20 benign endometrial tissues. We found that the expression of GPX3 was uniformly
down regulated in both rat and human EAC, regardless of tumor grade or histopathological subtype, implying that
the down-regulation is an early event in EAC. The rate of Gpx3 promoter methylation reaches 91%, where biallelic
methylation was present in 90% of the methylated tumors. The expression of the Met oncogene was slightly upre-
gulated in EACs that showed loss of expression of Gpx3, but no tumor suppressor activity of Gpx3/GPX3 was
detected. Preliminary results also suggest that the production of H2O2 is higher in rat endometrial tumors with
down-regulated Gpx3 expression. A likely consequence of loss of GPX3 protein function would be a higher amount
of ROS in the cancer cell environment. Thus, the results suggest important clinical implications of the GPX3 expres-
sion in EAC, both as a molecular biomarker for EAC and as a potential target for therapeutic interventions.
Background
Endometrial carcinoma (EC) is the most common gyne-
cological malignancy observed in the western society
with an incidence rate of approximately 15-20 per
100.000 women per year. Endometrioid adenocarcinoma
(EAC) arises from cells that form the glands in the
endometrium. It is the most prevalent subtype constitut-
ing approximately 80% of all endometrial cancers. Endo-
metroid andenocarcinoma can be histologically graded
according to the FIGO system (International Federation
of Gynecology and Obstretics) or classified as low grade
or high grade by an alternative architectural binary grad-
ing system. The disease maye i t h e rb ea ne s t r o g e n -
dependent low-grade endometroid variant (type I) or a
non-estrogen-dependent high grade variant (type II). As
expected, estrogen-dependent endometroid carcinomas
preferentially affect women in the pre- or peri-meno-
pausal phase, whereas type II EACs usually develops in
older post-menopausal women. Type II tumors are typi-
cally of high-grade endometroid adenocarcinomas, papil-
lary serous or clear cell types, and generally carry a poor
prognosis [1-5].
Due to the complexity of cancer etiology caused by
the genetic heterogeneity present in the human popula-
tion and the influences of environmental factors, it can
be advantageous to turn to inbred animal models. In the
present and previous works, we have used tumor mate-
rial from crosses including the BDII/Han rat model,
w h e r em o r et h a n9 0 %o ft h ef e m a l ev i r g i n so ft h eB D I I
inbred rat strain spontaneously develop endometrial
cancer during their life time. These tumors are hormone
dependent ECs and thus represent spontaneous hormo-
nal carcinogenesis [6-8].
In a recent comprehensive microarray study of endo-
metrial cancer cell lines, we found that the expressions
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any medium, provided the original work is properly cited.of 354 genes were significantly altered relative to nor-
mal/pre-malignant endometrium. When applying tradi-
tional statistical analyses and gene classification analysis
on the microarray data (Waikato environment of knowl-
edge analysis, Weka), we could identify a three-gene
signature (Gpx3, Bgn and Tgfb3), that might have
important implications in EAC carcinogenesis [9]. It was
also revealed that Gpx3 displayed the most significantly
altered gene expression in comparisons among endome-
trial tumors and normal/pre-malignant endometrium.
GPX3 constitutes the backbone of the cellular antioxi-
dant defense system, together with Superoxide Dismutase
(SOD) and Catalase (CAT)[10]. GPX3 catalyses the
reduction of peroxides and protects cells against oxida-
tive damage. The decreased mRNA expression of Gpx3
in rat endometrial tumors might result in an impaired
defense against endogenous and exogenous genotoxic
compounds, which could potentially lead to an increased
mutation rate including genes involved in carcinogenesis.
T h eg e n ee x p r e s s i o no fGPX3 in human has previously
been shown to be silenced in prostate cancer, ovarian
clear cell adenocarcinoma, gastric carcinoma and in Bar-
ret’s disease by epigenetic mechanisms, such as hyper-
methylation [11-16]. Furthermore, Yu, et al. [17-23], sug-
gested that GPX3 also contains tumor suppressor activity
by, directly or in-directly, regulating cell growth and pro-
liferation through unknown mechanisms. GPX3 may
influence the expression of MET (mesenchymal-epithelial
transition factor) that encodes a tyrosine kinase receptor
for hepatocyte growth factor (HGF). Abnormal expres-
sion/activation of the MET receptor has been reported in
numerous human cancer diseases [17-23].
The aim of this study was to investigate the mechan-
isms underlying the down-regulation of Gpx3 and
potential implications in EAC carcinogenesis. The pro-
duction of hydrogen peroxide in the endometrial tumors
displaying loss of Gpx3 expression as well as in the
endometrial samples with normal/high expression was
measured. Since GPX3 has been suggested to exhibit
tumor suppressor activity, that could regulate the tran-
scription of the oncogene, Met, we estimated the corre-
lation of the expression between Met and Gpx3 by
employing a real time RT-PCR expression study. In
order to verify the results from the BDII endometrial
cancer rat model in human, we also examined the
mRNA expression of GPX3 and MET in human endo-
metroid tumor samples of FIGO grade I, II and III and
benign samples.
Results
QPCR expression analysis of Gpx3 and Met
The statistical analyses applied for comparing replicates,
revealed no significant differences among the replicates
in either of the data sets. An average of the replicates Ct
value were used in the following calculations of the rela-
tive quantitative gene expression, the delta-delta Ct value.
The majority of the rat tumors displayed an almost
total loss of expression of Gpx3 whereas the non-/pre-
malignant endometrial samples displayed a normal/high
expression, as also shown by the highly significant dif-
ference among malignant and premalignant/normal
samples, (p < 0.001, Figure 1, Table 1). The mRNA
expression of GPX3 in the human material assessed in
30 human EACs in FIGO grade I-III (10 tumors from
each grade), and 21 benign endometrial samples differed
significantly between normal and malignant tissues (P <
0.001), but no differences among the different groups of
malignant tumors were seen (P > 0.5) (Table 2).
In the rat cell lines, the expression of the Met gene
was slightly higher among the malignant cell lines (P =
0.054). In the human material the expression of MET
was significantly lower among the malign tumors (P <
0.001), but there were no differences between FIGO
grades (P > 0.5) (Figure 1).
Epigenetic inactivation of the Gpx3 gene
The methylation status of the Gpx3 promoter region on
bisulfite treated DNA was examined with methylation
specific primers (MSP) in methylation-specific PCR of
the inbred rat strain BDII, one NME cell line and 15
EAC cell lines (Table 3). The NME cell line was not
methylated, while in the BDII rat strain and in 14 out of
15 EAC cell lines (93%), the Gpx3 promoter region was
hypermethylated of (Table 4).
Demethylation of the Gpx3 gene
Two of the tumor cell lines (NUT12 and NUT81) that
displayed Gpx3 promoter biallelic hypermethylation
were randomly selected for treatment with the demethy-
lating agent 5-aza-2´-deoxy-cy-tidine (5Aza-dC) in com-
bination with the histone deacetylace inhibitor,
trichostatin A (TSA) (Figure 2). As is shown, the Gpx3
mRNA expression was fully restored after the demethy-
lation treatment.
Reactive oxidative species (ROS) in cancer cells
The production of hydrogen peroxide in one rat endo-
metrial tumor cell line (NUT12) with loss of expression
of Gpx3 and in two non-malignant endometrial cell
lines (NUT43 and NUT56) with Gpx3 expression was
measured. A higher generation of hydrogen peroxide
was produced in the tumor cell line than in the prema-
lignant cell lines (Figure 3).
Deletion of the gene Gpx3 in the rat EAC tumor NUT84
FISH was performed on the cell line where Gpx3 was
unmethylated, but with a decreased gene expression of
Gpx3. The Gpx3 probe was generated from an NME
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exons of Gpx3 were designed and used in PCR
(Table 5). The PCR products were subsequently pooled,
amplified and fluorescently labeled in DOP-PCR. As a
positive control, we used a probe generated from a
RNO2 BAC. The result of the FISH experiment showed
that Gpx3 was deleted in the NUT84 cell line.
Discussion
Gpx3 was identified as a potential molecular biomarker
for rat EAC in a previous microarray study [9]. In this
study, we sought to confirm the previously demon-
strated down-regulation of Gpx3 expression from the
microarray study, of a selection of previously used rat
endometrial tumors (Table 1).
As indicated in the previous study, the rat tumors as
well as the human tumors indeed displayed an almost
total loss of expression of Gpx3, whereas the non-/pre-
malignant endometrial samples displayed a normal/high
expression, p < 0.001 (Figure 1). The mRNA expression
of GPX3 in the human material was measured in 30
human EACs in FIGO grade I-III (10 tumors from each
Figure 1 Gene expression of of Gpx3/GPX3 and Met/MET in rat and human. (a) Gpx3 expression in rat endometrial adenocarcinoma and
pre-malignant endometrial cell lines. (b) GPX3 gene expression in human endometrial adenocarcinomas of benign samples and FIGO grade I-III
tumor samples. (c) Gene expression of Met in rat endometrial adenocarcinoma and pre-malignant endometrial cell lines. (d) MET gene
expression in human endometrial adenocarcinomas of benign samples and FIGO grade I-III tumor samples. The median in each group is
represented by a horizontal line that indicates the mean delta delta Ct value in each group.
Table 1 Overview of the rat material and the tests performed in the study.
Sample Cell type Q-PCR
Gpx3
Q-PCR
Met
Methylation Demethylation H2O2 FISH
NUT43 NME X X X X
NUT56 NME X X X X
NUT6 EAC X X X
NUT12 EAC X X X X X
NUT31 EAC X X X
NUT39 EAC X X X
NUT46 EAC X X X
NUT50 EAC X X X
NUT51 EAC X X X
NUT52 EAC X X X
NUT81 EAC X X X X
NUT84 EAC X X X X
NUT127 EAC X X X
RUT5 EAC X
RUT12 EAC X X X
RUT13 EAC X X X
RUT30 EAC X X X
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(Table 2). Regardless of tumor grade, the expression of
GPX3 was low in all tumors, whereas the benign endo-
metrial tissues exhibited a relatively high expression.
Thus, in comparisons between tumor FIGO grades we
found no significant difference (p > 0.5), while between
malignant tumors and benign tissues, we found signifi-
cant differences, (p < 0.001) (Figure 1). These observa-
tions are in agreement with the down-regulated
expression of Gpx3 in the rat EACs described above.
Accordingly, the dramatic loss of Gpx3 expression in
almost all rat EAC samples and the consistently low
expression of GPX3 in human EAC, suggest that the
down-regulation of Gpx3 expression is an early event in
EAC carcinogenesis.
In a study performed by Yu et al. [17-23], it was sug-
gested that GPX3 has tumor suppressor activity as they
could show that induced over-expression of GPX3 in
prostate cancer cell lines decreased invasiveness, ancho-
rage independent growth and colony formation. More-
over, xenografted prostate cancer cells expressing GPX3,
showed reduction of tumor size, elimination of metasta-
sis and reduction of animal death. Their findings also
s u g g e s tt h a tt h eGPX3 tumor suppressor activity seems
to involve transcriptional regulation of the tumor onco-
gene, MET [12]. MET activation by HGF ligand binding,
initiates a whole spectrum of biological activities, includ-
ing growth promotion, motility and invasiveness [24].
Multiple signaling transduction pathways are induced by
MET engagement, including; the MAPK pathway, the
RAS pathway, the P13K pathway, the STAT pathway,
the beta catenin pathway and the Notch pathway [25].
To investigate whether Gpx3/GPX3 regulates the
expression of Met/MET in the rat EAC and human
tumor material, we performed qPCR on Met as well.
The expression of Met in the rat tumors was slightly
higher in the endometrial tumors with a loss of Gpx3
expression. Applying Pearsson´s correlation test, no sig-
nificant correlation between the Gpx3 and Met gene
expression was detected in the rat tumor material. Thus,
in the tumor materials included in this study, we could
not confirm any tumor suppressor activity of Gpx3.I n
the human material highly significant differences in the
expression of MET between normal and tumor tissues
were found (P < 0.001), but not in the way as would be
expected from previous studies, where it was suggested
that down regulation of GPX3 causes up-regulation of
MET in some cancer types [17-23]. Here, when GPX3
was down regulated, also the MET gene was down regu-
lated, which was also confirmed by the positive correla-
tion displayed by Pearsson´s correlation test (0.67, P <
0.001). Thus, in this study we could not detect any
tumor suppressor activity of GPX3 in MET/HGF
mediated pathways as suggested by Yu, et al. [17-23].
The GPX3 gene was shown to display epigenetic
inactivation in prostate cancer, ovarian clear cell
Table 2 Overview of the human material and the tests
performed in the study
Sample Tumor grade qPCR GPX3 qPCR MET
Lung normal X X
1-20 benign X X
21-30 I X X
31-40 II X X
41-50 III X X
Table 3 Methylation specific primer (MSP) pairs.
Primer pairs Forward primer Reverse primer Fragment size
(bp)
Methylated GTTGTTATTGGTTAGGAAGTTTTCG GCGTCTTAAAATAACCACCGTC 114
Unmethylated TTGTTATTGGTTAGGAAGTTTTTGG AACACATCTTAAAATAACCACCATC 116
Actb GGAAATCGTGCGTGACATTA AGGAAGGAAGGCTGGAAGAG 183
Methylation specific primer (MSP) pairs for Gpx3 used in the methylation specific PCR. The gene Actb was used as control.
Table 4 Methylation status of the Gpx3 promotor region
in the rat EAC cell lines.
Methylation status
Sample Cell type Methylated Unmethylated
BDII Strain DNA M+/M+
NUT43 NME M-/M-
NUT56 NME —————— ——————
NUT6 EAC M+/M+
NUT12 EAC M+/M+
NUT31 EAC M+/M+
NUT39 EAC M+/M-
NUT46 EAC M+/M+
NUT50 EAC M+/M+
NUT51 EAC M+/M+
NUT52 EAC M+/M+
NUT81 EAC M+/M+
NUT84 EAC M-/M-
NUT127 EAC M+/M+
RUT5 EAC M+/M+
RUT12 EAC M+/M+
RUT13 EAC M+/M+
RUT30 EAC M+/M+
* M+/M+ diallelic methylation, M+/M- monoallelic methylation,
M-/M- unmethylated, ———— no results available
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[11-16]. We therefore investigated the methylation sta-
tus in the BDII inbred rat strain, the EAC cell lines
with confirmed decreased mRNA expression (n = 14)
in the NME cell lines with a confirmed normal expres-
sion of Gpx3 (n = 2) (Figure 1). Hypermethylation of
the Gpx3 promoter region was found in 14 EAC cell
lines. Thirteen of the EAC samples the Gpx3 promoter
were biallelically methylated (Table 4), One tumor,
NUT39, showed monoallelic methylation and Gpx3
was therefore not as much down-regulated in this
tumor as in the tumors with biallelic hypermethylation,
which was also confirmed in the expression analysis
(Table 4). The premalignant samples (NME), with an
up-regulated expression of Gpx3, were not methylated.
Two of the tumor cell lines, NUT12 and NUT81, that
displayed biallelic hypermethylation of the Gpx3 promo-
ter, were selected for treatment with the demethylating
agent 5-aza-2´-deoxy-cy-tidine (5Aza-dC) in combina-
tion with the histone deacetylace inhibitor, trichostatin
A( T S A ) .T h eGpx3 mRNA expression was fully
restored after the demethylation treatment (Figure 2).
Hence, these results confirm that promoter methylation
plays an essential role in silencing of the Gpx3
expression.
Cancer cells are constantly exposed to oxidative stress,
and it has been shown that human tumor cell lines gen-
erate reactive oxidative species (ROS) to a much higher
extent than do non-transformed cell lines [26]. When
we measured the production of hydrogen peroxide in
two rat endometrial tumor cell lines with loss of expres-
sion of Gpx3 and in one premalignant/normal endome-
t r i a lc e l ll i n ew i t hn o r m a lGpx3 expression, we found
that a higher generation of hydrogen peroxide was pro-
duced in the tumor cell lines than in the premalignant
cell line (Figure 3). The loss of the protective properties
of Gpx3 most likely makes the endometrial cells more
vulnerable to ROS damage and genome instability.
These findings suggest that the GPX3 function is
impaired in endometroid adenocarcinoma, and a likely
consequence is an increased amount of hydrogen perox-
ide and other reactive oxidative species (ROS). Clearly,
more tumor cell lines have to be investigated and
further functional analyses are required to elucidate the
role of ROS in EAC.
In our study Gpx3 was strongly down regulated in
NUT84. From the result of the methylation studies of
this cell line it became clear to us that the loss
of expression did not depend on epigenetic inactivation
of the gene (Table 4). However, the down-regulation
may be explained by other mechanisms, such as struc-
tural aberrations at the site of the Gpx3 locus. In fact in
a previous study a chromosomal deletion has been
observed in the region of RNO10 where Gpx3 is located,
(RNO10q22, 40.3 Mb) which might explain the low
expression of the gene [27]. Consequently, we decided
t op e r f o r mF I S Ho nt h a tc e l ll i n ew i t haGpx3 probe
Figure 3 Measurements of hydrogen peroxide produced in
one endometrial tumor with loss of expression of Gpx3 and in
pre-malignant samples (NUT43 and NUT56) with Gpx3
expression.
Table 5 Primers used for the construction of the Gpx 3
specific probe.
Primer Sequence Product size
(bp)
Exon 1 F TTCTCCCCAAAACCACTGAG
R CCCTTCTCTCCCTCCTAAGC 583
Exon 2 F GTGGTCCCATGATGCTCTCT
R GGGTTCAAGATTTGGGTGTG 592
Exon 3 F CTGTAGCAGCCATCCAACTG
R ACCTTGTTCTGTCCGTCACC 588
Exon 4 F GAAGAGACAGGCTGGGTGAT
R CCCAAAGAGACCACCATCTC 589
Exon 5 F TCCATGTCAGCCACTCACTC
R GAAGTTGTAGGCCCTGAGA 594
Exon 6 F TAAGACTGATGCCCCCTCAC
R AGGTTTGAGCAGGACCATTG 587
Figure 2 Demethylation of endometrial tumor cell lines (NUT12
and NUT81) induced activation of Gpx3 transcription. The cells
were treated with the demethylating agent 5-aza-2´-deoxycytidine
(5Aza-dC) in combination with trichostatin A (TSA), a specific
inhibitor of histone deacetylase.
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with normal expression of Gpx3. From the results of the
FISH experiment, we could determine that Gpx3 was
included in the deletion of that was previously detected
[27], which explains the decreased expression of Gpx3
in NUT84. As the BDII rat strain did not exhibit a dele-
tion in the region including Gpx3 most probably the
deletion is an event that has occurred during the tumor
development.
Conclusion
We have found a consistent down-regulated expression
of Gpx3 in both rat and human EACs. The limited
expression of Gpx3 in the rat cell lines was correlated to
biallelic hyper-methylation of the Gpx3 promoter region.
Demethylation of the genomes resulted in a restored
expression, suggesting that the hypermethylation is
responsible for the down-regulation of Gpx3.F r o mt h e
FISH images we could confirm that the Gpx3 gene was
deleted in one of the tumors that was down regulated,
but not methylated (NUT84). In previous studies in
human prostate cancer, it was suggested that GPX3
exhibits tumor suppressor activity by transcriptional reg-
ulation of the oncogene MET [11-16]. We could not
confirm any such tumor suppressor activity of GPX3/
Gpx3 either in human or rat endometrial tumors.
It has been proposed that ROS overproduction is
required for hypoxic activation of HIF-1 [28] and the
results from the preliminary experiments in this study
indicate that the GPX3 function is impaired also in
endometroid adenocarcinoma. To conclude, the results
presented here propose that there are important clinical
implications of GPX3 expression in EAC, both as an
important molecular biomarker for EAC and as a poten-
tial target for therapeutic interventions.
Materials and methods
Animal crosses and tumor material
The animal material was derived from crosses between
BDII/Han females and males from two non-susceptible
rat strains, BN/Han and SPRDCu3/Han, where at first an
F1 progeny was produced. Subsequently, an F2 offspring
by brother/sister mating of the F1 progeny, and a back-
cross progeny (N1), by crossing the F1 males to BDII
females, were produced. The female progeny was pal-
pated twice each week for identification of uterine
tumors. Animals suspected to have tumors were eutha-
nized and the tumor tissue surgically removed, subjected
to pathological characterization and subsequently used to
establishment of cell cultures [29]. In this study we have
investigated cell lines established from tissues pathologi-
cally classified as endometrial adenocarcinomas (EAC)
and from tissues of normal/pre-malignant endometrium
(NME). RUT cell lines originate from tumors developed
in the F1 and F2 progeny and NUT cell lines originate
from the tumors in the backcross progeny (Table 1).
In vitro cell culture conditions
Primary cell cultures established from the EAC tumors
were propagated in Dulbecco’s modified Eagle medium,
supplemented with 100 IU/100 μg/ml penicillin/strepto-
mycin, L-glutamine, MEM amino acids, MEM Non
Essential Amino acids, MEM Vitamins solution and 10%
heat-inactivated fetal bovine serum, for 3-5 passages in
order to obtain the required amount of cells. The NME
cell lines were cultured under the same conditions, but
in medium containing 20% fetal bovine serum. The cells
w e r eg r o w na t3 7 ° Ci na na t m o s p h e r eo f9 5 %h u m i d i t y
and 5% CO2 and harvested by trypsinizination at a con-
fluence of 80-90% (approx 1x10
6 cells).
RNA extraction
Total RNA was extracted from the harvested cells of the
different endometrial rat cell lines with a KingFisher mL
Instrument (Thermo Electron Corporation, USA)
according to the manufacturer’s protocol (MagAttract
Tissue Mini M48 Kit, Qiagen). RNA was spectrophoto-
metrically quantified (NanoDrop technologies, USA).
Quantitative PCR (qPCR) of Gpx3 and Met in cell lines
from adenocarcinomas (EAC) and normal/premalignant
tissue (NME)
A total of 14 EAC and 2 NME cell lines were used in
qPCR analysis with GAPDH as an endogenous control
and Universal Rat Reference RNA, Agilent Technologies,
Inc as a calibrator (Table 1). RT-PCR was performed
using High Capacity cDNA Reverse Transcription Kit
according to the manufacturer’s protocol (Applied Bio-
systems). Template cDNA was added to TaqMan Uni-
versal Master Mix (AB; Applied Biosystems, Foster City,
CA, USA) in a 12.5 μl reaction with specific pre-
designed probes for the Gpx3 and Met (Applied Biosys-
tems). Reactions were performed in duplicates and
threshold cycle number was averaged. Relative gene
expression quantification was calculated according to
the comparative Ct method using GAPDH as an endo-
genous control and Universal Rat reference RNA (Stra-
tagene) as calibrator. The relative quantitative gene
expression, were determined as follows: 2-(Ct sample-Ct
calibrator), where Ct values of the calibrator and sample
are determined by subtracting the Ct value of the target
gene from the value of the GAPDH gene.
Bisulfite treatment and methylation-specific PCR
One μg DNA from the susceptible rat strain BDII, 15
EAC and 2 NME cell lines were denatured, sodium
bisulfite treated and purified using Epitect Bisulfite Kit
according to the manufacturer’s protocol (Qiagen)
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trial cell line (NUT43) with a normal expression of
Gpx3, and thus unmethylated was treated with methy-
lase and subsequently treated with sodium bisulfite. The
modified tumor/control DNA was used as template for
methylation-specific PCR. Methylation specific primers
(MSP) were designed using the publicly available Meth-
Primer program http://www.urogene.org/methprimer/
[30]. The bisulphite modification of DNA converts
unmethylated cytosines to uracils, whereas methylated
cytosines will remain unchanged. Bisulphite treated
DNA was amplified with either methylation specific or
un-methylation specific primer sets. PCR was carried
out in a final 25 μl volume containing 50 ng of template
DNA The mixture was heated at 94°C for 1 min and
then subjected to 35 cycles of 94°C, 55°C and 72°C and
a final extension at 72°C for 7 min. The PCR product
was analyzed on a 2% agarose gel with appropriate size
marker and the absence or presence of PCR product
were detected.
5-aza-2´-deoxycytidine and trichostatin A (TSA)
treatment in rat endometrial tumor cell lines
Two EAC cell lines (NUT12 and NUT81) with con-
firmed biallelic methylated promoter status of Gpx3
were treated with 5-aza-2´-deoxycytidine and trichosta-
tin A (Sigma). Cells were grown in a medium containing
2.5 μM 5-aza-cytidine for 96 hours, with the medium
and drug being replaced every 24 hours and the addition
of 300 nM TSA was added for the last 16 hours. After
96 hours, the drugs were removed and total RNA for
Gpx3 RT-PCR expression analysis was extracted using
AllPrep RNA/DNA Mini Kit according to the manufac-
turer’s protocol (Qiagen).
Hydrogen peroxide measurements
The intra- and extra-cellular amount of hydrogen perox-
ide in the endometrial cell lines were measured using
the Amplex® Red Peroxide/Peroxidase Hydrogen assay
kit according to the manufacturer’s protocol (Molecular
Probes, Invitrogen). The three cell lines investigated
(NUT12, NUT43, NUT56) were seeded to a 96 wells
plate (Corning) with an initial number of 5000 cells/well
(Table 1). In each well, the amount of hydrogen perox-
ide was measured post 72 hours of incubation, as
described above. Each cell line was replicated 20 times.
The cells were lysated by adding RIPA buffer (25 mM
TRIS-HCl pH 7.6, 150 mM NaCl, 1% deoxycholate, 0,
1% SDS and 1% NP40) followed by incubation on ice
for 30 minutes. Intra- and extra-cellular H2O2 concen-
trations were assessed by pooling 50 μlo fc e l ll y s a t e
with 50 μl of used cell culture media.
Development of FISH probes for Gpx3
DNA from the pre-malignant cell line, NUT43, with a
normal expression of Gpx3 was used to generate a
probe that represented only the Gpx3 gene. Six primer
pairs, specific for the Gpx3 gene, with a product size
of approximately 600 base pair each (Table 5), were
designed by using the Primer 3 program available on
the internet: http://fokker.wi.mit.edu/primer3/input.
htm. Amplification was performed by PCR and carried
out in a final 25 μl volume containing 100 ng of tem-
plate DNA. The mixture was heated at 94°C for 1 min
and then subjected to 35 cycles of 94°C, 58°C and 72°C
and a final extension at 72°C for 7 min. Sizes of the
PCR products were determined on a 2% agarose gel
w i t ha na p p r o p r i a t es i z em a r k e r .T h eP C Rp r o d u c t s
were then purified by Mini Elute PCR purification kit
(QIAGEN) and the concentration of DNA was mea-
sured by NanoDrop (NanoDrop Technologies, USA)
amplified product. The amplified sequences were then
pooled and fluorescently labeled by dNTP in DOP-
PCR and subsequently used as a Gpx3 specific probe
in FISH.
One probe, which was used as positive control, was
developed from a RNO2 BAC clone (CH230-397A17
from BACPAC Resources Center, Oakland, California).
The BAC DNA was amplified by DOP-PCR as follows.
The reactions were performed in a final volume of
25 μl and with a BAC DNA concentration of 20 ng/μl.
T h em i x t u r ew a sh e a t e da t9 4 ° Cf o r1m i na n dt h e n
subjected to 35 cycles of 94°C, 55°C and 72°C and a
final extension at 72°C for 7 min. The product was
verified on a 2% agarose gel with an appropriate size
marker. For FISH, the Nick Translation kit from
Abbott molecular was used according to the manufac-
tures protocol.
Human material
A total of 30 EACs in FIGO grade I-III (10 tumors from
each grade embedded in archival formalin fixed paraffin
(FFPE) were used in the study. Apart from the endome-
trial tumors, 21 benign endometrial tissues were col-
lected, and reference material from lung was used in the
normalization process (Table 2). All samples were anon-
ymous. A pathologist marked the tumor area in samples
in the hematoxylin and eosin slide. Using a Tissue
Micro Array-equipment (Pathology Devices), 3-4 cores
(∅0.6 mm) of tumor tissue was punched out from the
paraffin block. After standard tissue sample deparaffini-
zation using xylene and alcohols, samples were lyzed in
a Tris-chloride, EDTA, sodium dodecyl sulfate (SDS)
and proteinase K containing buffer. RNA was then
extracted and used for the real time qPCR.
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Total RNA was extracted and used for qPCR according
to the same procedure as for the rat samples.
Statistical analysis
For statistical evaluations of Ct values for differences
among replicates we applied paired samples t-test and
for comparisons of normal and malignant tissues inde-
pendent sample t-test was applied. (PASW Statistics 18,
SPSS Inc, Chicago, USA). In both tests the null hypoth-
eses were assuming no differences between replicates,
and no differences between tissue types respectively.
The Pearson correlation test was performed to check for
correlation between the expression of Gpx3 and Met.
The significance levels were set to P < 0.5 in all statisti-
cal tests.
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